Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the lungs’ arteries. The increased pressure in the vessels may be caused by obstruction in the lung’s small arteries for various reasons. The exact cause of PAH is unknown, and although treatable, there is no permanent cure for the disease. PAH usually affects women between the ages of 30-60. However, individuals with PAH may go years without a diagnosis, either because the symptoms may be mild, nonspecific, or only present during demanding exercise.
Johnson & Johnson and United Therapeutics Corp – Notable Market Players in Pulmonary Arterial Hypertension Market
The pulmonary arterial hypertension market comprises top players such as Johnson & Johnson, Gilead Sciences Inc, United Therapeutics Corp, Bayer AG, Aerami Therapeutics Holdings Inc, Novartis AG, GSK Plc, Teva Pharmaceutical Industries Ltd, Lupin Ltd, and Pfizer Inc.
The companies listed above are implementing various strategies that have resulted in the company’s growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the pulmonary arterial hypertension market:
|
Year |
News |
| May-2022 | United Therapeutics Corporation received the U.S. Food and Drug Administration (FDA) approval of Tyvaso DPI (treprostinil) inhalation powder for treating PAH; WHO Group 1, and PH-ILD; WHO Group 3 to improve exercise ability. Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the FDA for use in PAH and PH-ILD. |
| Sep-2020 | Johnson & Johnson company Janssen Pharmaceutical submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for UPTRAVI (selexipag) as an injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults with WHO functional class (FC) II–III, who were prescribed oral UPTRAVI but are temporarily unable to take oral therapy. |
| Aug-2020 | United Therapeutics Corporation announced that the U.S. Food and Drug Administration (FDA) accepted the supplemental New Drug Application (sNDA) for review of Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). |
